[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553140":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":31,"locations":10,"responsibleParty":36,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":44,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":10,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":10},{"fullName":5,"class":6},"Sinovac (Dalian) Vaccine Technology Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vaccination group",null,"The last dose of varicella vaccine given 30 days before enrollment was manufacture by Sinovac (Dalian) Vaccine Technology Co. LTD.,(Sinovac).",[13],"Biological: Varicella vaccine",{"label":15,"type":10,"description":16,"interventionNames":10},"Non-vaccination group","Without varicella vaccine history",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"BIOLOGICAL","Varicella vaccine","lyophilized powder,subcutaneous injection",[9],[24,28],{"name":25,"affiliation":26,"role":27},"Xiaoqiang Liu","Yunnan Provincial Center for Disease Control and Prevention","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":30,"role":27},"Zhiqiang Xie","Henan Provincial Center for Disease Control and Prevention",[32],{"name":25,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","15911568282","lxq7611@126.com",{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100553140","correlation-of-protection-against-varicella-in-an-exploratory-study-100553140",false,"NCT06482216","Correlation of Protection Against Varicella in an Exploratory Study","Inclusion Criteria:\n\n* 1-12 years children who were the siblings or children of the indicator varicella cases, or the deskmates\u002Froommates of the indicator varicella cases;\n* Having close contacts with the indicator varicella cases at least 2 days during the period from 5 days before the onset and 2 days after the onset;\n* Without varicella vaccination history or having varicella vaccination history (the last dose of varicella was manufacured by Sinovac, with an interval of \\>30 days before enrollment)\n* Subjects\u002Flegal guardian can understand and sign the informed consent;\n* Being able to provide legal proof of identity.\n\nExclusion Criteria:\n\n* Without varicella history;\n* Body temperature ≥37.0℃ on the day of enrollment, or skin rash on the head, torso, and limbs;\n* Having any confirmed or suspected immunodeficiency disorder, including tumor patients undergoing chemotherapy, human immunodeficiency virus (HIV) infection, continuous use of steroid hormones for more than 30 days (prednisone equivalent ≥2mg\u002Fkg days in children), or having other immunosuppressive disorder as determined by the clinician;\n* The investigators considered that participation in this study was not appropriate for various other reasons.",true,"ALL","1 Year","12 Years",{"count":49,"type":50},400,"ESTIMATED","OBSERVATIONAL","This study consists of two parts. Part 1 is a retrospective cohort study and part 2 is a prospective cohort study. In Part 1 ,the scaled logit model was used to assess the correlation between varicella-zoster virus (VZV) antibody titers using fluorescent-antibody-to-membrane-antigen assay (FAMA) 30 days after varicella vaccine immunization and the risk of subsequent varicella breakout\u002Fdisease , to determine the protective threshold for achieving FAMA antibodies. Part 2 was to validate the model in part 1.",[54],"Varicella","NOT_YET_RECRUITING","2025-01-23",{"date":58,"type":59},"2025-01-27","ACTUAL",{"date":61,"type":50},"2025-10-10",{"date":63,"type":50},"2028-10-10",{"name":5,"class":6}]